World's Best Scientists 2026 revealed!
Isabelle Poizot-Martin

Isabelle Poizot-Martin

D-Index & Metrics

Microbiology

D-Index
44
Citations
7274
World Ranking
5145
National Ranking
314

Isabelle Poizot-Martin publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Isabelle Poizot-Martin sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 234 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Isabelle Poizot-Martin D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Isabelle Poizot-Martin sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 44 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Isabelle Poizot-Martin is a researcher affiliated with Aix-Marseille University in France. Their work primarily spans the field of medicine, with an emphasis on epidemiology, infectious diseases, oncology, hepatology, and virology.

The scientist's research is notably centered on HIV/AIDS, viral-associated cancers, and hepatitis virus studies. Key topics covered include HIV/AIDS research and interventions, viral-associated cancers and disorders, hepatitis C virus research, HIV research and treatment, HIV/AIDS drug development and treatment, HIV-related health complications and treatments, and hepatitis B virus studies.

Recent publications authored or co-authored by Isabelle Poizot-Martin include:

  • CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies, 2020, Clinical Infectious Diseases
  • Spectrum and Incidence Trends of AIDS- and Non-AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort, 2020, Cancer Epidemiology Biomarkers & Prevention
  • Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death, 2020, Journal of Hepatology
  • VIH et cancer: mise au point en 2020, 2020, Bulletin du Cancer
  • Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma, 2022, Cancers

Their frequent collaborators include colleagues Linda Wittkop, Claudine Duvivier, Philippe Sogni, Firouzé Bani-Sadr, and Olivier Bouchaud. The scientist regularly publishes in journals such as Clinical Infectious Diseases, Bulletin du Cancer, Cancers, Journal of Antimicrobial Chemotherapy, and Journal of Hepatology.

Isabelle Poizot-Martin's contributions emphasize the intersection of infectious diseases and oncology, particularly focusing on the complications and manifestations of HIV and hepatitis virus co-infections. The work includes both clinical epidemiological investigations and broader studies into the treatment and outcomes of affected populations.

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy

    Thierry Saint-Marc;Maria Partisani;Isabelle Poizot-Martin;Franck Bruno

  • Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

    Thierry Saint-marc;Maria Partisani;Isabelle Poizot-martin;Olivier Rouviere

  • Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected Patients

    Magid Herida;Murielle Mary-Krause;Régis Kaphan;Jacques Cadranel

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

    Joseph J. Eron;Bonaventura Clotet;Jacques Durant;Christine Katlama

  • Visceral leishmaniasis and HIV-1 co-infection in southern France.

    Eric Rosenthal;Pierre Marty;Isabelle Poizot-Martin;Jacques Reynes

  • Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.

    S. Grabar;C. Pradier;E. le Corfec;R. Lancar

  • Frequency, determinants and consequences of delayed access to care for HIV infection in France.

    Emilie Lanoy;Murielle Mary-Krause;Pierre Tattevin;Isabelle Perbost

  • The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

    Perrine Roux;Perrine Roux;M. Patrizia Carrieri;M. Patrizia Carrieri;Virgine Villes;Virgine Villes;Pierre Dellamonica

  • Endothelial cell dysfunction in HIV infection.

    Lafeuillade A;Alessi Mc;Poizot-Martin I;Boyer-Neumann C

  • Retention in Opioid Substitution Treatment: A Major Predictor of Long-Term Virological Success for HIV-Infected Injection Drug Users Receiving Antiretroviral Treatment

    Perrine Roux;Perrine Roux;M. Patrizia Carrieri;M. Patrizia Carrieri;Julien Cohen;Julien Cohen;Isabelle Ravaux

  • Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.

    Eric Rosenthal;Isabelle Poizot-Martin;Thierry Saint-Marc;Jean-Philippe Spano

  • A large French prospective cohort of HIV-infected patients: the Nadis Cohort.

    P Pugliese;L Cuzin;A Cabié;I Poizot-Martin

  • Risk factors of chronic kidney disease in HIV-infected patients.

    Philippe Flandre;Pascal Pugliese;Lise Cuzin;Corinne Isnard Bagnis

  • Hepatitis E virus infection in patients infected with the human immunodeficiency virus

    Mamadou Kaba;Hervé Richet;Isabelle Ravaux;Jacques Moreau

  • Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

    Chloe Orkin;Jean-Michel Molina;Eugenia Negredo;José R Arribas

  • The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study.

    Emilie Lanoy;Jean-Philippe Spano;Fabrice Bonnet;Marguerite Guiguet

  • A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients

    François Raffi;Jean-Pierre Aboulker;Christian Michelet;Véronique Reliquet

  • Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4)

    Murielle Mary-Krause;Sophie Grabar;Laurence Lièvre;Sophie Abgrall

  • Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection.

    Catherine Tamalet;Christophe Pasquier;Nouara Yahi;Philippe Colson

  • Simplification Therapy with Once-Daily Emtricitabine, Didanosine, and Efavirenz in HIV-1–Infected Adults with Viral Suppression Receiving a Protease Inhibitor–Based Regimen: A Randomized Trial

    Jean-Michel Molina;Valérie Journot;Laurence Morand-Joubert;Patrick Yéni

  • Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

    Joly;Burdet C;Landman R;Vigan M

  • Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients

    Clotilde Allavena;Matthieu Hanf;Matthieu Hanf;David Rey;Claudine Duvivier

Frequent Co-Authors

André Cabié
André Cabié Grenoble Alpes University
Jacques Reynes
Jacques Reynes University of Montpellier
Catherine Tamalet
Catherine Tamalet Aix-Marseille University
Philippe Morlat
Philippe Morlat University of Bordeaux
Christine Katlama
Christine Katlama Sorbonne University
Dominique Salmon
Dominique Salmon Université Paris Cité
Cécile Goujard
Cécile Goujard University of Paris-Saclay
Gilles Pialoux
Gilles Pialoux Tenon Hospital
Karine Lacombe
Karine Lacombe Hôpital Saint-Antoine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students studying Microbiology in the USA, exploring related online degrees can open diverse career pathways beyond the laboratory. One growing field is health information management, where professionals manage critical healthcare data. Pursuing online health information management programs cahiim accredited ensures access to quality education that meets industry standards.

Another promising avenue is medical billing and coding, essential roles that support healthcare administration. Many learners opt for quick, flexible options like an online medical billing and coding certificate fast program to jumpstart their careers efficiently.

Certification plays a crucial role in career advancement. Obtaining a cpc certification can significantly boost job prospects and earning potential in medical coding. Career opportunities also exist in health information management jobs, with salaries reflecting the growing demand for skilled professionals. Explore detailed insights on health information management jobs salary to understand the financial benefits.

Best Scientists Citing Isabelle Poizot-Martin

Trending Scientists

Recently Published Articles